Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week phase 3 study of fluticasone furoate + vilanterol versus fluticasone propionate + salmeterol in COPD
2010-023419-33Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone, vilanterol, fluticasone propionate and salmeterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline trough in 24-hour weighted mean serial FEV1 at week 12. Started Jan 2011; status: completed.
02
Drugs
fluticasonevilanterolfluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-023419-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023419-33.